- Home
- CTMX vs EVMN Comparison
CTMX vs EVMN Comparison
Compare CTMX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTMX | EVMN |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 892.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CTMX | EVMN |
|---|---|---|
| Price | $4.84 | $23.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $8.86 | ★ $44.17 |
| AVG Volume (30 Days) | ★ 2.5M | 952.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $138,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | ★ 36.45 | N/A |
| 52 Week Low | $0.40 | $13.89 |
| 52 Week High | $6.35 | $33.20 |
Technical Indicators
Market Signals| Indicator | CTMX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 45.30 |
| Support Level | $3.83 | $21.86 |
| Resistance Level | $6.20 | $23.08 |
| Average True Range (ATR) | 0.32 | 2.36 |
| MACD | -0.08 | -0.73 |
| Stochastic Oscillator | 16.01 | 13.67 |
Price Performance
Historical ComparisonAbout CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.